M
Miklos Egyed
Researcher at University of Pécs
Publications - 77
Citations - 2248
Miklos Egyed is an academic researcher from University of Pécs. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 19, co-authored 52 publications receiving 1666 citations.
Papers
More filters
Journal ArticleDOI
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.
Heinz Ludwig,Roman Hájek,Elena Tothova,Johannes Drach,Zdenek Adam,Boris Labar,Miklos Egyed,Ivan Spicka,Heinz Gisslinger,Richard Greil,Ingrid Kuhn,Niklas Zojer,Axel Hinke +12 more
TL;DR: Thalidomide-dexamethasone with melphalan-prednisolone resulted in a higher proportion of complete and very good remissions, and overall responses, compared with MP, and Toxicity was higher with TD, particularly in patients older than 75 years with poor performance status.
Journal ArticleDOI
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa,Alessandro M. Vannucchi,Adam J. Mead,Miklos Egyed,Anita Szoke,Aleksandr Suvorov,János Jakucs,Andrew C. Perkins,Ritam Prasad,Jiri Mayer,Judit Demeter,Peter Ganly,Jack W. Singer,Huafeng Zhou,James P. Dean,Peter A. W. te Boekhorst,Jyoti Nangalia,Jean-Jacques Kiladjian,Jean-Jacques Kiladjian,Claire N. Harrison +19 more
TL;DR: Pacritinib therapy was well tolerated and induced significant and sustained SVR and symptom reduction, even in patients with severe baseline cytopenias, and could be a treatment option for patients with myelofibrosis, including those with baseline cy topenias for whom options are particularly limited.
Journal ArticleDOI
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Ruben A. Mesa,Jean-Jacques Kiladjian,John Catalano,Timothy Devos,Miklos Egyed,Andrzei Hellmann,Donal McLornan,Kazuya Shimoda,Elliott F. Winton,Wei Deng,Ronald L. Dubowy,Julia D. Maltzman,Francisco Cervantes,Jason Gotlib +13 more
TL;DR: In JAKi-naïve patients with myelofibrosis, 24 weeks of momelotinib treatment was noninferior to ruxolitinib for spleen response but not for symptom response.
Journal ArticleDOI
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Andrew D. Zelenetz,Jacqueline C. Barrientos,Jennifer R. Brown,Bertrand Coiffier,Julio Delgado,Miklos Egyed,Paolo Ghia,Árpád Illés,Wojciech Jurczak,Paula Marlton,Marco Montillo,Franck Morschhauser,Alexander S. Pristupa,Tadeusz Robak,Jeff P. Sharman,David Simpson,Lukas Smolej,Eugen Tausch,Adeboye H. Adewoye,Lyndah Dreiling,Yeonhee Kim,Stephan Stilgenbauer,Peter Hillmen +22 more
TL;DR: Ielalisib plus BR is superior to BR alone, improving PFS and OS, and represents an important new treatment option for patients with R/R CLL.
Journal ArticleDOI
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Francesco Passamonti,Martin Griesshammer,Francesca Palandri,Miklos Egyed,Giulia Benevolo,Timothy Devos,Jeannie Callum,Alessandro M. Vannucchi,Serdar Sivgin,Caroline Bensasson,Mahmudul Khan,Nadjat Mounedji,Güray Saydam +12 more
TL;DR: This study assessed the efficacy and safety of ruxolitinib in controlling disease in patients with polycythaemia vera without splenomegaly who need second-line therapy and the proportion of patients achieving haematocrit control at week 28.